Artiva Biotherapeutics (ARTV) Total Liabilities (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Total Liabilities data on file, last reported at $18.1 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $18.1 million, down 19.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.1 million (down 19.45% YoY), and the FY2025 annual result was $21.0 million, down 8.59% from the prior year.
• Total Liabilities eased to $18.1 million in Q1 2026 per ARTV's latest filing, from $21.0 million in the prior quarter.
• Over five years, Total Liabilities peaked at $174.7 million in Q1 2024 and troughed at $18.1 million in Q1 2026.
• A 4-year average of $61.7 million and a median of $23.8 million in 2024 frame the typical range for Total Liabilities.
• On a YoY basis, Total Liabilities climbed as much as 8.59% in 2025 and fell as far as 87.13% in 2025.
• A 4-year view of Total Liabilities shows it stood at $50.7 million in 2023, then slumped by 54.77% to $22.9 million in 2024, then fell by 8.59% to $21.0 million in 2025, then retreated by 13.65% to $18.1 million in 2026.
• Business Quant data shows ARTV's Total Liabilities at $18.1 million in Q1 2026, $21.0 million in Q4 2025, and $19.6 million in Q3 2025.